Lutetium-177 (Lu-177) PSMA therapy (Pluvicto) is a new theranostic treatment that targets a specific molecule on the surface of prostate cancer cells, effectively killing the cancer cells …

2021年6月23日 · Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand …

2024年1月20日 · Metastatic castration-resistant prostate cancer presents treatment challenges, including the side effects of chemotherapy. Mayo Clinic researchers find that lutetium-177 …

177 Lutetium PSMA-617 (brand name Pluvicto) is a type of therapy known as PSMA (prostate-specific membrane antigen) targeted ligand therapy. It is prescribed for patients diagnosed …

2023年1月24日 · ASCO recently published a rapid recommendation systemic therapy update on lutetium-177 (177 Lu)-PSMA-617 (vipivotide tetraxetan) for metastatic castration-resistant …

Lutetium-177 Prostate Specific Membrane Antigen (Lu-177 PSMA) therapy is a personalised treatment that aims to relieve symptoms and potentially slow the growth and spread of a …

Lutetium-177 PSMA therapy is an innovative molecular therapy used to treat advanced prostate cancer, also known as metastatic prostate cancer (cancer that has spread from the prostate to …

2022年3月23日 · 177 Lutetium-PSMA-617 (Lu-PSMA) is now FDA-approved for patients with metastatic castration-resistant prostate cancer who have received certain other treatments …

Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen …

2022年3月23日 · Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC that combines a targeting compound (ligand) with a therapeutic …